A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination With Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) in the Treatment of Metastatic Pancreatic Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Tumour cell vaccine-GVAX (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin; Pegfilgrastim
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 21 Feb 2019 Planned End Date changed from 1 Dec 2019 to 1 Jan 2021.
- 21 Feb 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2021.
- 21 Feb 2019 Status changed from suspended to active, no longer recruiting.